In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant.
Studies of feline leukemia virus (FeLV) have illustrated the importance of the genotype of the infecting virus in determining disease outcome. In FeLV infections, as in other retroviral infections, it is less clear how virus variants that evolve from the transmitted virus affect pathogenesis. We previously reported an analysis of the genotypic changes that occur in the viral envelope gene (env) in cats infected with a prototype transmissible FeLV clone, 61E (J. Rohn, M. Linenberger, E. Hoover, and J. Overbaugh, J. Virol. 68:2458-2467, 1994). In one cat, each variant (81T) had evolved, in addition to scattered amino acid changes, a four-amino-acid insertion with respect to 61E. This insertion was located at the same site in the extracellular envelope glycoprotein where the immunodeficiency-inducing molecular clone 61C possesses a six-amino-acid insertion critical for its pathogenic phenotype, although the sequences of the insertions were distinct. To determine whether acquisition of the four-amino-acid insertion was associated with a change in the replication or cytopathic properties of the virus, we constructed chimeras encoding 81T env genes in a 61E background. One representative chimeric virus, EET(TE)-109, was highly cytopathic despite the fact that it replicated with delayed kinetics in the feline T-cell line 3201 compared to the parental 61E virus. The phenotype of this virus was also novel compared to other FeLVs, including both the parental virus 61E and the immunodeficiency-inducing variant 61C, because infection of T cells was associated with syncytium formation. Moreover, in single-cycle infection assays, the 81T-109 envelope demonstrated receptor usage properties distinct from those of both 61E and 61C envelope. Thus, these studies demonstrate the evolution of a novel T-cell cytopathic and syncytium-inducing FeLV in the host. The 81T virus will be valuable for dissecting the mechanism of T-cell killing by cytopathic variants in the FeLV model.
Rohn
J L
JL
Department of Microbiology, University of Washington, Seattle 98195, USA.
Moser
M S
MS
Gwynn
S R
SR
Baldwin
D N
DN
Overbaugh
J
J
D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D005075:Biological Evolution; D002415:Cats; D002460:Cell Line; D003001:Cloning, Molecular; D003588:Cytopathogenic Effect, Viral; D004279:DNA, Viral; D005434:Flow Cytometry; D018628:Gene Dosage; D015752:Genes, env; D014644:Genetic Variation; D015726:Giant Cells / Q000821:virology; D007700:Kinetics; D005256:Leukemia Virus, Feline / Q000235:genetics* / Q000472:pathogenicity* / Q000502:physiology; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction / Q000379:methods; D011991:Receptors, Virus / Q000378:metabolism; D013601:T-Lymphocytes / Q000821:virology; D014407:Tumor Cells, Cultured; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000378:metabolism; D014779:Virus Replication
D004279:DNA, Viral; D011991:Receptors, Virus; D014759:Viral Envelope Proteins; C074548:feline leukemia virus receptor